Nuwiq (Octapharma) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A. It is a fourth-generation recombinant product produced in human embryonic kidney cells, thus eliminating any potential source of non-human mammalian proteins with antigenic potential. Nuwiq is indicated for on-demand, prophylactic, and perioperative use in both adults and children. Octapharma developed Nuwiq and has exclusively marketed the drug since 2014.
LIST OF FIGURES
9 Figure 11: Datamonitor Healthcare’s drug assessment summary of Advate for hemophilia
10 Figure 10: Datamonitor Healthcare’s drug assessment summary of Adynovate for hemophilia
12 Figure 12: AMT-061 for hemophilia – SWOT analysis
LIST OF TABLES 5 Table 1: Nuwiq drug profile
7 Table 2: Nuwiq pivotal trial data in hemophilia
13 Table 3: Nuwiq sales for hemophilia across the US and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.